Manhattan Scients (MHTX) 0.0850 $MHTX
Manhattan Scientifics Recruits Robert R. Proulx as Its New President and Chief Operating Officer for Its Senior Scientific Subsidiary
Business Wire - Wed Jan 14, 8:00AM CST
Manhattan Scientifics, Inc. (OTCQB:MHTX) has recruited Robert R. Proulx (pronounced "Pru"
to the position of President and Chief Operating Officer of its Senior Scientific LLC subsidiary, effective January 12. As previously announced, Gerald Grafe, former president of Senior Scientific, is remaining with Senior Scientific to focus on strategic relationships and intellectual property issues. Edward R. Flynn, PhD, founder of Senior Scientific, is remaining as Chief Scientist.
Manhattan Scientifics Announces Expansion of Executive Team at Its Senior Scientific Subsidiary
Business Wire - Tue Dec 30, 10:00AM CST
Manhattan Scientifics, Inc. (OTCQB:MHTX) is recruiting a seasoned executive to oversee Senior Scientific's next stage of product development for its MRX diagnostic technology for the early detection of cancer. The new President and COO candidate under consideration, has a strong background in the life sciences and experience in diagnostic medical product development. The new President/COO will be responsible for expanding the collaborations in place with the MD Anderson Cancer Center in Houston and The University of New Mexico Health Sciences Center, Albuquerque, to help further develop this technology.
Manhattan Scientifics raises USD2.0m equity
M2 - Mon Nov 24, 8:15AM CST
Manhattan Scientifics, Inc. (OTC: MHTX) said it has completed a USD2.0 million equity raise.
Manhattan Scientifics Completes $2.0 Million Equity Raise
Business Wire - Fri Nov 21, 8:00AM CST
Manhattan Scientifics, Inc. (OTCQB:MHTX) (the "Company" has completed a $2.0 million equity raise. Details of the raise are available in the Company's November 18th 8K filing with the SEC. The proceeds will primarily be used to fund the advancement, demonstration and validation of its MRX cancer diagnostic technology under development by its subsidiary, Senior Scientific, LLC.
The Life Sciences Report Interviews SeeThruEquity Regarding Microcap Life Sciences Companies
ACCESSWIRE - Wed Nov 05, 8:24AM CST
New York, NY / ACCESSWIRE / November 5, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it was recently interviewed by The Life Sciences Report regarding the microcap market for life sciences companies, during which SeeThruEquity analysts discussed DelMar Pharmaceuticals Inc. (OTCQB: DMPI), Manhattan Scientifics Inc. (OTCQB: MHTX) and TapImmune Inc. (OTCQB: TPIV).
Manhattan Scientifics Engages Dian Griesel Int'l.
Business Wire - Thu Oct 30, 6:45AM CDT
Manhattan Scientifics, Inc. (OTCQB: MHTX) has engaged Dian Griesel Int'l. (DGI) to manage media relations. DGI will work toward the objective of increasing awareness of the company and its subsidiary Senior Scientific LLC, which has developed and patented technologies that use bio safe nanoparticles and sensitive magnetic sensors to detect and measure cancer cells more rapidly and less expensively than current methods.
SeeThruEquity Issues Company Note on Manhattan Scientifics, Highlighting MRX Technology Featured in MD Anderson Presentation
ACCESSWIRE - Mon Oct 13, 8:00AM CDT
New York, NY / ACCESSWIRE / October 13, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on Manhattan Scientifics, Inc. (OTCQB: MHTX).
Manhattan Scientifics' Unparalleled Cancer Measurement Technology Featured in MD Anderson Presentation
Business Wire - Wed Oct 08, 7:49AM CDT
Senior Scientific LLC, a subsidiary of Manhattan Scientifics, Inc. (OTCQB: MHTX), is currently collaborating with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a cancer detection and measurement technology originally developed by Edward R. Flynn, PhD. John D. Hazle, PhD of the MD Anderson Cancer Center recently presented initial results from the collaboration in a poster at the World Molecular Imaging Conference in Seoul, South Korea. The link to the results can be found here - http://www.mhtx.com/wmic/2014-poster.pdf.
Manhattan Scientifics Issues Follow up Report to Shareholders -"Pushing the Limits of Cancer Detection"
Business Wire - Thu Oct 02, 7:28AM CDT
Three months ago Manhattan Scientifics (OTCQB: MHTX) announced the delivery of its 1st breakthrough cancer measurement instrument to M.D. Anderson Cancer Center in Houston.
SeeThruEquity Issues Quarterly Update on Manhattan Scientifics, Highlighting Spencer Falk's Lead Role in MRX Commercialization Efforts
ACCESSWIRE - Wed Aug 27, 8:01AM CDT
New York, NY / ACCESSWIRE / August 27, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update on Manhattan Scientifics, Inc. (OTCQB: MHTX) for Q2 2014.
JNJ: 99.62 (+1.18), MRK: 58.81 (-0.07)
Manhattan Scientifics Reaches the Fork (Falk) in the Road
Business Wire - Tue Aug 19, 7:54AM CDT
Spencer Falk, whose marketing expertise was mission-critical to the blockbuster success of Viagra and Celebrex, among other medical brands, today announced that he would lead the commercialization of early cancer detection technology for Senior Scientific, a division of Manhattan Scientifics (OTCQB:MHTX). Mr. Falk previously held senior marketing positions at Pfizer and Forest Laboratories, and has had a 35-year career in the pharmaceutical and diagnostic sector fields.
JNJ: 99.62 (+1.18), MRK: 58.81 (-0.07)
Manhattan Scientifics Analyst Report; Potentially Disruptive Emerging Technology Play - Monetizing Intellectual Property is the Goal by BrokerBank Securities, Inc.
PR Newswire - Tue Jul 01, 7:30PM CDT
Manhattan Scientifics, Inc. (OTCQB: MHTX) MHTX is an emerging technology incubator/venture firm focused on technology transfer and commercialization of disruptive technologies in the nanomedicine space. The company is presently developing commercial medical prosthetics applications for its ultrafine grain metals and plans to commercialize the cancer research work and nanomedical applications developed by Senior Scientific LLC, a unit of the Company.
SeeThruEquity Issues Company Note on Manhattan Scientifics
ACCESSWIRE - Thu Jun 26, 8:02AM CDT
Company Announces Delivery of MRX II Cancer Detection Instrument to MD Anderson
Manhattan Scientifics Recruits Robert R. Proulx as Its New President and Chief Operating Officer for Its Senior Scientific Subsidiary
Business Wire - Wed Jan 14, 8:00AM CST
Manhattan Scientifics, Inc. (OTCQB:MHTX) has recruited Robert R. Proulx (pronounced "Pru"
to the position of President and Chief Operating Officer of its Senior Scientific LLC subsidiary, effective January 12. As previously announced, Gerald Grafe, former president of Senior Scientific, is remaining with Senior Scientific to focus on strategic relationships and intellectual property issues. Edward R. Flynn, PhD, founder of Senior Scientific, is remaining as Chief Scientist. Manhattan Scientifics Announces Expansion of Executive Team at Its Senior Scientific Subsidiary
Business Wire - Tue Dec 30, 10:00AM CST
Manhattan Scientifics, Inc. (OTCQB:MHTX) is recruiting a seasoned executive to oversee Senior Scientific's next stage of product development for its MRX diagnostic technology for the early detection of cancer. The new President and COO candidate under consideration, has a strong background in the life sciences and experience in diagnostic medical product development. The new President/COO will be responsible for expanding the collaborations in place with the MD Anderson Cancer Center in Houston and The University of New Mexico Health Sciences Center, Albuquerque, to help further develop this technology.
Manhattan Scientifics raises USD2.0m equity
M2 - Mon Nov 24, 8:15AM CST
Manhattan Scientifics, Inc. (OTC: MHTX) said it has completed a USD2.0 million equity raise.
Manhattan Scientifics Completes $2.0 Million Equity Raise
Business Wire - Fri Nov 21, 8:00AM CST
Manhattan Scientifics, Inc. (OTCQB:MHTX) (the "Company"
has completed a $2.0 million equity raise. Details of the raise are available in the Company's November 18th 8K filing with the SEC. The proceeds will primarily be used to fund the advancement, demonstration and validation of its MRX cancer diagnostic technology under development by its subsidiary, Senior Scientific, LLC. The Life Sciences Report Interviews SeeThruEquity Regarding Microcap Life Sciences Companies
ACCESSWIRE - Wed Nov 05, 8:24AM CST
New York, NY / ACCESSWIRE / November 5, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it was recently interviewed by The Life Sciences Report regarding the microcap market for life sciences companies, during which SeeThruEquity analysts discussed DelMar Pharmaceuticals Inc. (OTCQB: DMPI), Manhattan Scientifics Inc. (OTCQB: MHTX) and TapImmune Inc. (OTCQB: TPIV).
Manhattan Scientifics Engages Dian Griesel Int'l.
Business Wire - Thu Oct 30, 6:45AM CDT
Manhattan Scientifics, Inc. (OTCQB: MHTX) has engaged Dian Griesel Int'l. (DGI) to manage media relations. DGI will work toward the objective of increasing awareness of the company and its subsidiary Senior Scientific LLC, which has developed and patented technologies that use bio safe nanoparticles and sensitive magnetic sensors to detect and measure cancer cells more rapidly and less expensively than current methods.
SeeThruEquity Issues Company Note on Manhattan Scientifics, Highlighting MRX Technology Featured in MD Anderson Presentation
ACCESSWIRE - Mon Oct 13, 8:00AM CDT
New York, NY / ACCESSWIRE / October 13, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on Manhattan Scientifics, Inc. (OTCQB: MHTX).
Manhattan Scientifics' Unparalleled Cancer Measurement Technology Featured in MD Anderson Presentation
Business Wire - Wed Oct 08, 7:49AM CDT
Senior Scientific LLC, a subsidiary of Manhattan Scientifics, Inc. (OTCQB: MHTX), is currently collaborating with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a cancer detection and measurement technology originally developed by Edward R. Flynn, PhD. John D. Hazle, PhD of the MD Anderson Cancer Center recently presented initial results from the collaboration in a poster at the World Molecular Imaging Conference in Seoul, South Korea. The link to the results can be found here - http://www.mhtx.com/wmic/2014-poster.pdf.
Manhattan Scientifics Issues Follow up Report to Shareholders -"Pushing the Limits of Cancer Detection"
Business Wire - Thu Oct 02, 7:28AM CDT
Three months ago Manhattan Scientifics (OTCQB: MHTX) announced the delivery of its 1st breakthrough cancer measurement instrument to M.D. Anderson Cancer Center in Houston.
SeeThruEquity Issues Quarterly Update on Manhattan Scientifics, Highlighting Spencer Falk's Lead Role in MRX Commercialization Efforts
ACCESSWIRE - Wed Aug 27, 8:01AM CDT
New York, NY / ACCESSWIRE / August 27, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update on Manhattan Scientifics, Inc. (OTCQB: MHTX) for Q2 2014.
JNJ: 99.62 (+1.18), MRK: 58.81 (-0.07)
Manhattan Scientifics Reaches the Fork (Falk) in the Road
Business Wire - Tue Aug 19, 7:54AM CDT
Spencer Falk, whose marketing expertise was mission-critical to the blockbuster success of Viagra and Celebrex, among other medical brands, today announced that he would lead the commercialization of early cancer detection technology for Senior Scientific, a division of Manhattan Scientifics (OTCQB:MHTX). Mr. Falk previously held senior marketing positions at Pfizer and Forest Laboratories, and has had a 35-year career in the pharmaceutical and diagnostic sector fields.
JNJ: 99.62 (+1.18), MRK: 58.81 (-0.07)
Manhattan Scientifics Analyst Report; Potentially Disruptive Emerging Technology Play - Monetizing Intellectual Property is the Goal by BrokerBank Securities, Inc.
PR Newswire - Tue Jul 01, 7:30PM CDT
Manhattan Scientifics, Inc. (OTCQB: MHTX) MHTX is an emerging technology incubator/venture firm focused on technology transfer and commercialization of disruptive technologies in the nanomedicine space. The company is presently developing commercial medical prosthetics applications for its ultrafine grain metals and plans to commercialize the cancer research work and nanomedical applications developed by Senior Scientific LLC, a unit of the Company.
SeeThruEquity Issues Company Note on Manhattan Scientifics
ACCESSWIRE - Thu Jun 26, 8:02AM CDT
Company Announces Delivery of MRX II Cancer Detection Instrument to MD Anderson
